Voquezna Price With Medicare in 2026: What You'll Actually Pay

Direct Answer: Does Medicare Cover Voquezna in 2026?

It depends on your specific Medicare Part D or Medicare Advantage drug plan. Voquezna (vonoprazan) is a newer, patented potassium-competitive acid blocker, so many 2026 Part D formularies either exclude it entirely or place it on a non-preferred brand or specialty tier requiring prior authorization and step therapy through cheaper generic PPIs first. Without formulary coverage, expect to pay $829 to $1,013 for a 30-day supply in 2026.

What Original Medicare Part D Covers for Voquezna

Original Medicare (Medicare Part A for hospital insurance and Medicare Part B for medical insurance) never pays for outpatient prescription drugs like Voquezna. You need a standalone Part D Prescription Drug Plan (PDP) paired with Original Medicare, or drug coverage bundled into a Medicare Advantage plan. Most 2026 Part D formularies place newer potassium-competitive acid blockers like Voquezna behind generic proton pump inhibitors (omeprazole, pantoprazole, esomeprazole) that cost pennies to a few dollars a month on Tier 1 or Tier 2.

When Voquezna is listed, it typically sits on Tier 3 (non-preferred brand) or Tier 4 (specialty), both of which trigger prior authorization and often step therapy documenting that you tried and failed a generic PPI or H2 blocker first. Check any specific plan's formulary using the Medicare Plan Finder at medicare.gov before you enroll, since coverage of the exact tablet strength (10 mg versus 20 mg) can vary plan by plan.

What Medicare Advantage (MA-PD) Plans May Add

Most Medicare Advantage plans bundle prescription drug coverage (MA-PD) using the same tiering and utilization-management tools as standalone PDPs, but each insurer negotiates its own rebates and formulary placement with Phathom Pharmaceuticals, so Voquezna's tier and prior-authorization rules can differ meaningfully from a standalone Part D plan even within the same insurer's product line. A handful of Medicare Advantage plans that emphasize gastroenterology or specialty-drug management have added Voquezna to a preferred specialty tier in 2026, but most still require prior authorization confirming a diagnosis that matches Voquezna's FDA-approved indications.

Search by exact drug name and dosage at medicare.gov/plan-compare to see whether the Medicare Advantage plans available in your county cover Voquezna and at what tier. Because Medicare Advantage networks and formularies are county-specific, a plan covering Voquezna at a manageable copay in one county may exclude it entirely in a neighboring one.

Cost Without Coverage in 2026

A 30-day supply of 30 Voquezna 20 mg tablets costs roughly $829 to $1,013 at retail pharmacies in 2026 when no insurance applies, based on pricing trackers such as GoodRx and SingleCare. Pharmacy discount cards can lower the cash price to roughly $580 to $830 for the same 30-day supply, though you cannot combine a discount-card price with your Part D copay on the same transaction; the pharmacy applies whichever price is lower for you.

Voquezna Triple Pak and Dual Pak, the H. pylori-eradication combination packs, run a similar cash range for the 14-day treatment course because the packaging bundles vonoprazan with generic antibiotics (amoxicillin, clarithromycin) that are individually inexpensive. If your plan does cover Voquezna, your actual cost depends on where you are in the 2026 Part D benefit: up to $615 toward the deductible, then 25% coinsurance during the initial coverage phase, then $0 after your out-of-pocket spending on covered drugs reaches the $2,100 annual cap.

Getting Voquezna Covered: Prior Authorization and Formulary Exceptions

When your Part D or MA-PD plan denies or excludes Voquezna, your prescriber can submit a formulary exception request explaining why a covered alternative, typically a generic PPI, is not appropriate for you, such as a documented allergy, an inadequate response to at least one generic PPI, or a drug interaction. CMS requires Part D plans to respond to standard exception requests within 72 hours and expedited (urgent) requests within 24 hours.

If the plan still denies coverage, you can file a formal appeal, called a redetermination, within 60 days, and escalate through up to five levels of appeal, including an Independent Review Entity, if the redetermination fails. Because Voquezna competes directly with decades-old generic PPIs that Part D plans strongly prefer for cost reasons, an exception request works best when your doctor documents a specific clinical reason vonoprazan is needed rather than requesting it as a first-line drug.

Alternatives If Your Plan Doesn't Cover Voquezna

When Voquezna is not on your plan's formulary or your copay is still too high after a denied exception, several lower-cost options address the same conditions.

• Generic proton pump inhibitors (omeprazole, pantoprazole, esomeprazole, lansoprazole): FDA-approved for erosive esophagitis and GERD, almost always Tier 1 or Tier 2 with copays of $0 to $15 a month in 2026, and the first-line therapy most Part D plans require you to try before approving Voquezna.
• H2 blockers (famotidine): a cheaper, lower-potency acid reducer covered on nearly every Part D formulary at Tier 1, useful for milder heartburn symptoms while you pursue a Voquezna exception.
• Extra Help (Part D Low-Income Subsidy): if you qualify based on income and resources, Extra Help caps your Voquezna copay at $4.90 to $12.65 per fill in 2026, whichever tier it lands on, once your plan covers it.
• Phathom Pharmaceuticals patient assistance: the standard Voquezna Savings Card excludes anyone enrolled in Medicare, Medicaid, or another government drug program, but Phathom's separate charitable patient-assistance channel, reached through voquezna.com or your prescriber, evaluates Medicare beneficiaries case by case for free or reduced-cost drug based on income.
• Pharmacy discount comparison: before filling at your Part D copay, ask your pharmacist to run a GoodRx or SingleCare cash-price comparison. If the discount-card price is lower than your copay, especially before you meet your deductible, paying cash can cost less, though it will not count toward your Part D out-of-pocket total.

Extra Help and the Dual-Eligible Angle

About 12 million Americans are dual-eligible for Medicare and Medicaid, and most are automatically enrolled in Extra Help without a separate application. For dual-eligible beneficiaries with full Medicaid benefits, Voquezna copays, when the drug is covered by the Part D plan, are typically $0 to $4.90 in 2026, well below the retail cash price.

Beneficiaries who qualify for Extra Help based on income alone, up to 150% of the federal poverty level, about $23,940 for an individual in 2026, but don't have full Medicaid, still get the capped copay of $4.90 to $12.65 per brand-name fill. If your state runs a State Pharmaceutical Assistance Program, it may further reduce Voquezna's cost on top of Extra Help; availability and rules vary by state, so check with your State Health Insurance Assistance Program (SHIP) counselor.

Does Original Medicare cover Voquezna?

No, not directly. Original Medicare (Part A and Part B) never covers outpatient prescription drugs like Voquezna. You need a standalone Medicare Part D Prescription Drug Plan paired with Original Medicare, and even then, coverage depends on whether that specific plan's 2026 formulary includes Voquezna and at what tier.

Does Medicare Advantage cover Voquezna?

It depends on the plan. Most Medicare Advantage plans with drug coverage (MA-PD) set their own formulary and tier placement for Voquezna, so coverage and copay vary by insurer and by county. Check the Medicare Plan Finder at medicare.gov/plan-compare using the exact drug name and dosage to see what plans in your area cover.

How much does Voquezna cost without Medicare coverage in 2026?

A 30-day, 30-tablet supply of Voquezna costs roughly $829 to $1,013 at retail pharmacies in 2026 without insurance. Pharmacy discount cards such as GoodRx or SingleCare can lower the cash price to about $580 to $830 for the same supply, though you cannot combine a discount price with your Part D copay in the same transaction.

What are cheaper alternatives to Voquezna?

Generic proton pump inhibitors, including omeprazole, pantoprazole, esomeprazole, and lansoprazole, are FDA-approved for erosive esophagitis and GERD and typically cost $0 to $15 a month on Tier 1 or Tier 2 of most 2026 Part D formularies. H2 blockers like famotidine are an even cheaper option for milder symptoms.

Does Extra Help lower the cost of Voquezna?

Yes, but only if your Part D or MA-PD plan already covers Voquezna at some tier. In 2026, Extra Help caps your copay at $4.90 to $12.65 per fill for brand-name drugs like Voquezna, regardless of the plan's normal tier pricing. Extra Help does not force a plan to add a drug to its formulary.

What is Voquezna prescribed for?

Voquezna (vonoprazan) is FDA-approved for healing erosive esophagitis, relief of heartburn associated with erosive and non-erosive GERD, and, as Voquezna Triple Pak or Dual Pak in combination with antibiotics, treatment of H. pylori infection. It is a potassium-competitive acid blocker, a different drug class than traditional proton pump inhibitors.

How do I appeal if my Part D plan denies Voquezna?

Your prescriber can first request a formulary exception, which the plan must answer within 72 hours (24 hours if expedited). If denied, you can file a formal appeal called a redetermination within 60 days, and escalate through up to five levels of appeal, including an Independent Review Entity, if that also fails.

What's the difference between Voquezna and a standard PPI like omeprazole?

Voquezna (vonoprazan) is a potassium-competitive acid blocker that suppresses stomach acid production differently and often faster than proton pump inhibitors like omeprazole. Clinically, both treat erosive esophagitis and GERD, but Voquezna is a newer, patent-protected brand, so it costs far more and faces tighter Medicare formulary restrictions than generic PPIs.